Tempus Ai Cl A (TEM) Stock Price, Quote & News

Company Profile

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also...

Industry: Health Information Services

Sector: Healthcare

Phone: 800 976 5448

Fax: 800 893 0276

Website: www.tempus.com

Address:

600 West Chicago Avenue, Suite 510, Chicago, United States

TheBigUpski May. 9 at 1:07 AM

$TEM don’t know anything about $TEM but I wouldn’t take this guys advice. Check out his advice on $IREN

0 · Reply

onefryshy May. 8 at 8:04 PM

$TEM Peg it at $50 for the options expiration.

1 · Reply

capitalthinktank May. 8 at 7:36 PM

$TEM is absolutely coiling in a massive intraday range today — this is pure compression before expansion type of price action. No clean direction yet, just heavy two-way flow with buyers and sellers constantly fighting for control. You can feel volatility building under the surface even if price looks “stuck” on the chart. This is the kind of setup traders watch closely because wide ranges like this rarely stay quiet for long. Eventually, one side gets exhausted and the move expands fast. Key focus now: range break + volume confirmation. Until then, it’s chop, noise, and positioning battle. Big moves usually don’t start with clarity — they start exactly like this: messy, wide, and indecisive. 👉If this helps, tap @capitalthinktank

1 · Reply

HyacinthCohen May. 8 at 7:34 PM

$TEM Ok fellow bulls, which one of you guys have law degree and tell me how likely these lawsuits will be dropped. According to my researching, they're all going away. But, i have very limited experience with corporate law for situations like these.

1 · Reply

Alican1994 May. 8 at 7:28 PM

$TEM Buy now don't complain later

0 · Reply

Alican1994 May. 8 at 7:26 PM

$TEM 10 more at 49

0 · Reply

Kreeft May. 8 at 7:14 PM

$TEM still

0 · Reply

ChipDistribution7 May. 8 at 7:04 PM

Not financial advice. Pelosi trades are still getting attention — reported ~87% win rate, strong 2024 vs S&P 500. But the real takeaway is positioning, not hype. 2025: names like $NVDA, $GOOGL, $VST, $TEM saw big upside after entries. Recent filings: partial profit-taking in mega-cap tech, then re-entry via 2027 LEAPS (long-dated leverage reset). Buffett side: ~$380B cash pile + cautious tone on valuations. Two styles: * Pelosi: stay in AI momentum with leverage * Buffett: hold cash, wait for reset Market decides. Follow me 👉@ChipDistribution7 for real-time updates and everything. Let’s make moves!

0 · Reply

405strong May. 8 at 6:38 PM

$TEM ehh.phkers, illegal algos wont let it close green....they going to drop it

0 · Reply

zerohedge2018 May. 8 at 6:28 PM

$TEM I would sell this stock. Its going nowhere. And it has not do go down to be a bad stock But their are enough other opportunities where the stock price is in an uptrend, not so Tempus. Perhaps in 1 year. Are you willing to wait 1 year without any movement in stock price?

0 · Reply

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

2026-05-07T14:10:10.000Z - 1 day ago

Tempus AI announces proposed convertible senior notes offering

2026-05-07T12:30:22.000Z - 1 day ago

Cathie Wood’s ARK Investment buys 146K shares of Tempus AI today

May 7, 2026, 7:11 AM EDT - 1 day ago

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

2026-05-07T09:05:35.000Z - 2 days ago

Tempus AI price target lowered to $59 from $68 at Baird

2026-05-07T06:36:13.000Z - 2 days ago

Tempus AI price target raised to $68 from $65 at TD Cowen

2026-05-07T06:21:33.000Z - 2 days ago

Lucent Diagnostics announces collaboration with Tempus AI

QTRX

May 6, 2026, 8:00 AM EDT - 2 days ago

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

QTRX

2026-05-05T20:35:01.000Z - 3 days ago

Tempus AI reports Q1 adjusted EPS (13c), consensus (20c)

2026-05-05T20:33:33.000Z - 3 days ago

Tempus AI raises FY26 revenue view to $1.59B-$1.6B from $1.59B, consensus $1.59B

May 5, 2026, 4:30 PM EDT - 3 days ago

Tempus AI Earnings Call Transcript: Q1 2026

May 5, 2026, 4:01 PM EDT - 3 days ago

Tempus Reports First Quarter 2026 Results

Apr 29, 2026, 8:30 AM EDT - 9 days ago

Tempus to Host Inaugural Investor Day on May 29, 2026

Apr 28, 2026, 8:30 AM EDT - 10 days ago

Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026

2026-04-23T12:49:32.000Z - 15 days ago

Tempus, USC announce strategic collaboration to accelerate precision medicine

Apr 23, 2026, 8:30 AM EDT - 15 days ago

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

Apr 21, 2026, 8:30 AM EDT - 17 days ago

Tempus to Report First Quarter 2026 Financial Results on May 5

2026-04-15T12:44:13.000Z - 23 days ago

Tempus AI, Predicta Biosciences announces expansion of GenoPredicta

Apr 15, 2026, 8:30 AM EDT - 23 days ago

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

Apr 14, 2026, 11:45 AM EDT - 24 days ago

Tempus AI Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-14T12:52:15.000Z - 24 days ago

Tempus AI announces 31 abstracts for presentation at AACR annual meeting

Apr 14, 2026, 8:30 AM EDT - 24 days ago

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

2026-04-13T19:45:12.000Z - 25 days ago

tempus AI Inc Class A call volume above normal and directionally bullish

2026-04-13T12:48:28.000Z - 25 days ago

Tempus AI launches automated ‘Active Follow-Up’ service

Apr 13, 2026, 8:30 AM EDT - 25 days ago

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care

2026-04-13T09:45:06.000Z - 26 days ago

Tempus AI upgraded to Buy from Hold at TD Securities

2026-04-12T23:51:40.000Z - 26 days ago

Tempus AI initiated with an Underperform at Jefferies

2026-04-09T14:18:53.000Z - 4 weeks ago

Tempus AI announce strategic collaboration with Gilead

GILD

Apr 9, 2026, 8:30 AM EDT - 4 weeks ago

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

GILD

Apr 8, 2026, 4:01 PM EDT - 4 weeks ago

Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 1, 2026, 8:30 AM EDT - 5 weeks ago

Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

Mar 17, 2026, 8:30 AM EDT - 7 weeks ago

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Mar 11, 2026, 8:30 AM EDT - 2 months ago

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Mar 3, 2026, 12:15 PM EST - 2 months ago

Tempus AI Transcript: Morgan Stanley Technology, Media & Telecom Conference 2026

Mar 3, 2026, 8:30 AM EST - 2 months ago

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Feb 26, 2026, 8:30 AM EST - 2 months ago

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

Feb 24, 2026, 4:30 PM EST - 2 months ago

Tempus AI Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:01 PM EST - 2 months ago

Tempus Reports Fourth Quarter and Full Year 2025 Results

Feb 19, 2026, 11:01 AM EST - 2 months ago

Is TEM Stock A Buy At $60?

Feb 18, 2026, 8:30 AM EST - 2 months ago

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

Feb 12, 2026, 4:05 PM EST - 3 months ago

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

Feb 12, 2026, 4:05 PM EST - 3 months ago

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States

Feb 10, 2026, 8:30 AM EST - 3 months ago

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

Feb 4, 2026, 7:00 AM EST - 3 months ago

Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

Feb 2, 2026, 7:00 AM EST - 3 months ago

Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

Jan 27, 2026, 8:30 AM EST - 3 months ago

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

Jan 26, 2026, 11:14 AM EST - 3 months ago

Tempus Logix Launches AI-Powered Calculator to End Hidden Fees and Price Fluctuation in Auto Transport

Jan 21, 2026, 8:30 AM EST - 3 months ago

Tempus Announces the Launch of Paige Predict

Jan 12, 2026, 4:30 PM EST - 4 months ago

Tempus AI Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:30 AM EST - 4 months ago

Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

Jan 12, 2026, 8:00 AM EST - 4 months ago

Here's why the Tempus AI stock may surge 47% soon

Jan 12, 2026, 7:00 AM EST - 4 months ago

Northwestern Medicine Selects Tempus to Expand Genomic Testing

Jan 11, 2026, 5:30 PM EST - 4 months ago

Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

Jan 11, 2026, 5:00 PM EST - 4 months ago

Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results

Jan 8, 2026, 8:30 AM EST - 4 months ago

Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium

Jan 8, 2026, 8:15 AM EST - 4 months ago

Rune Labs Taps Tempus Exec as New CEO to Expand AI-Enabled Neurology Care

Jan 6, 2026, 8:30 AM EST - 4 months ago

Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 8:30 AM EST - 5 months ago

Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium

Dec 3, 2025, 10:30 AM EST - 5 months ago

Tempus AI Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 8:30 AM EST - 6 months ago

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 14, 2025, 8:30 AM EST - 6 months ago

Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research

Nov 13, 2025, 10:00 AM EST - 6 months ago

Tempus AI Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 8:30 AM EST - 6 months ago

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

Nov 4, 2025, 4:30 PM EST - 6 months ago

Tempus AI Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:01 PM EST - 6 months ago

Tempus Reports Third Quarter 2025 Results

Oct 28, 2025, 8:30 AM EDT - 6 months ago

Tempus to Participate in the Stifel 2025 Healthcare Conference

Oct 21, 2025, 8:30 AM EDT - 7 months ago

Tempus to Report Third Quarter 2025 Financial Results on November 4

Oct 20, 2025, 9:00 AM EDT - 7 months ago

Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity

Oct 16, 2025, 8:30 AM EDT - 7 months ago

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

WHWK

Oct 15, 2025, 8:30 AM EDT - 7 months ago

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Oct 9, 2025, 8:30 AM EDT - 7 months ago

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

Oct 1, 2025, 12:24 PM EDT - 7 months ago

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

Sep 22, 2025, 4:30 PM EDT - 8 months ago

Overlooked Stock: TEM Taps All-Time High on FDA Clearance

TheBigUpski May. 9 at 1:07 AM

$TEM don’t know anything about $TEM but I wouldn’t take this guys advice. Check out his advice on $IREN

0 · Reply

onefryshy May. 8 at 8:04 PM

$TEM Peg it at $50 for the options expiration.

1 · Reply

capitalthinktank May. 8 at 7:36 PM

1 · Reply

HyacinthCohen May. 8 at 7:34 PM

1 · Reply

Alican1994 May. 8 at 7:28 PM

$TEM Buy now don't complain later

0 · Reply

Alican1994 May. 8 at 7:26 PM

$TEM 10 more at 49

0 · Reply

Kreeft May. 8 at 7:14 PM

$TEM still

0 · Reply

ChipDistribution7 May. 8 at 7:04 PM

0 · Reply

405strong May. 8 at 6:38 PM

$TEM ehh.phkers, illegal algos wont let it close green....they going to drop it

0 · Reply

zerohedge2018 May. 8 at 6:28 PM

0 · Reply

405strong May. 8 at 6:22 PM

$TEM can we at least close 50.00+ today Please This was 55 a day ago

0 · Reply

roblake29 May. 8 at 6:09 PM

$TEM Curious about Tempus AI? Read my take on it here. I believe it could become a health technology powerhouse, advancing data-driven precision medicine into the new age: https://seekingalpha.com/article/4901567-tempus-ai-my-pick-for-oncoming-boom-in-demand-data-driven-precision-medicine

0 · Reply

Alican1994 May. 8 at 6:07 PM

$TEM 20 more little by little

0 · Reply

RobotMumba100 May. 8 at 6:06 PM

$TEM under 50$ this is free money. AS I said DON'T PANIC for the last news.... it's a finacial settlement more convenient for $TEM AI precision medicine in the next 5 year will be gold for early investors

0 · Reply